Uni-Bio Science Group Limited is excited to announce that the China National Medical Products Administration ("NMPA") has officially approved the marketing application for BOGUTAI® (teriparatide injection) on January 16, 2024. This significant milestone h
2024-01-22
View detailsUni-Bio Science 2023 Interim Results,Achieved Record High Profit of HK$39.4M,Driven by Scale-Up Operations and Remarkable Growth in Marketed Drugs,Expanding Multiple Channels and Diverse Commercialization for New Products
2023-08-29
View detailsUni-Bio Science Announces 2022 Annual Results,Record High Turnover of HK$440.3 Million and HK$38.5 Million Profit Achieved Expanding Portfolio with New Drug Innovations and Strategic R&D Partnerships
2023-03-28
View detailsFrom February 23, Uni-Bio Science Group's 2023 Annual Strategy Conference was held in Beijing, attended by the Chairman, CEO, heads and colleagues of the BU.
2023-03-13
View detailsFrom February 15 to 17, Uni-Bio Science Group's 2023 Annual Marketing Conference was held in Xiamen, attended by the Chairman and CEO of Uni-Bio and all front-line marketing backbones from all units across the country. Embarking on a new journey, many new
2023-03-01
View details